Collaborative Research and Development Agreement, Optional Extension Period

No definition available.

Name:	cdxs_CollaborativeResearchandDevelopmentAgreementOptionalExtensionPeriod
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Duration of License Agreement

+ References

No definition available.

+ Details

Name:	cdxs_DurationofLicenseAgreement
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Estimated proceeds

+ References

No definition available.

+ Details

Name:	cdxs_Estimatedproceeds
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue Recognition, Milestone Method, Additional Milestones, Maximum Milestone Receivable

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionMilestoneMethodAdditionalMilestonesMaximumMilestoneReceivable
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue Recognition, Milestone Method, Additional Milestones, Minimum Milestone Receivable

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionMilestoneMethodAdditionalMilestonesMinimumMilestoneReceivable
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue Recognition, Milestone Method, Termination Notice Period

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionMilestoneMethodTerminationNoticePeriod
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue Recognition, Milestone Method, Term of Milestone Agreement

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionMilestoneMethodTermofMilestoneAgreement
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue Recognition, Period for Recognition

+ References

No definition available.

+ Details

Name:	cdxs_RevenueRecognitionPeriodforRecognition
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Right of Refusal Period

+ References

No definition available.

+ Details

Name:	cdxs_RightofRefusalPeriod
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Revenue, Maximum Contingent Proceeds

+ References

No definition available.

+ Details

Name:	cdxs_RoyaltyRevenueMaximumContingentProceeds
Namespace Prefix:	cdxs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Term of collaborative research and development agreement.

+ References

No definition available.

+ Details

Name:	cdxs_TermOfCollaborativeResearchAndDevelopmentAgreement
Namespace Prefix:	cdxs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	cdxs_AgreementTypeAxis=cdxs_TechnologyTransferCollaborationandLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MajorCustomersAxis=cdxs_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MajorCustomersAxis=cdxs_MerckMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	cdxs_AgreementTypeAxis=cdxs_SupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements (Details) - USD ($)	1 Months Ended					3 Months Ended		5 Months Ended	9 Months Ended
Collaborative Arrangements (Details) - USD ($)	Apr. 30, 2016	Sep. 30, 2015	Aug. 31, 2015	Jul. 31, 2014	Feb. 29, 2012	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Technology Transfer, Collaboration and License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Termination notice period			30 days
GlaxoSmithKline [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from license fees received				$ 6,000,000
Revenue recognized	$ 7,500,000	$ 6,500,000						$ 5,000,000
Minimum milestone receivable						$ 5,750,000.00
Maximum milestone receivable						38,500,000.0
Termination notice period				90 days
Term of milestone agreement				3 years
License and services revenue						0	$ 500,000		$ 3,000,000	$ 1,500,000
Deferred revenue						0			0		$ 3,000,000
Merck [Member] \| Technology Transfer, Collaboration and License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from license fees received			$ 5,000,000
Revenue recognized		$ 5,000,000
Estimated proceeds						8,000,000			8,000,000
Termination notice period			90 days
License and services revenue						600,000	$ 400,000		1,900,000	400,000
Deferred revenue						2,100,000			2,100,000		4,000,000
Upfront License fee, period for recognition			2 years
Potential royalty revenue						15,000,000
Duration of license agreement							3 years
Right of refusal period			5 years
Merck [Member] \| Supply Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Termination notice period					24 months
License and services revenue						300,000	$ 500,000		1,000,000	$ 1,500,000
Deferred revenue						$ 1,700,000			$ 1,700,000		$ 1,000,000
Upfront License fee, period for recognition					5 years
Term of collaborative research and development agreement (years)					5 years
Optional extension period					5 years